Searching. Please wait…
1582
37
171
29406
4423
2606
347
392
Abstract: CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare and heterogeneous group of lymphoproliferative disorders. Known variants of CD20-negative DLBCL include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease and anaplastic lymphoma kinase-positive DLBCL. Given the lack of CD20 expression, atypical cellular morphology and aggressive clinical behavior characterized by chemotherapy resistance and inferior survival rates, CD20-negative DLBCL represents a challenge from the diagnostic and therapeutic perspectives. The goals of the present review are to summarize the current knowledge on the biology of the distinct variants of CD20-negative DLBCL, provide future therapeutic directions based on the limited preclinical and clinical data available, and increase awareness concerning these rare malignancies among pathologists and clinicians.
Fuente: Expert Review of Hematology Volume 8, 2015 - Issue 3, Pages 343-354
Publisher: Taylor & Francis
Publication date: 01/02/2015
No. of pages: 12
Publication type: Article
DOI: 10.1586/17474086.2015.1007862
ISSN: 1747-4086,1747-4094
Publication Url: http://dx.doi.org/10.1586/17474086.2015.1007862
Google Scholar
Citations
Read publication
CASTILLO, JORGE J.
CHÁVEZ, JULIO C.
HERNANDEZ-ILIZALITURRI, FRANCISCO J.
SANTIAGO MONTES MORENO
Back